Section 174 Rd Amortization Manufacturers

For four years, manufacturers watched a punitive change to Section 174 grind through their cash flow. Instead of deducting research and experimental costs in the year they were incurred, plants had to capitalize and amortize those costs over five years for domestic work and fifteen for foreign work. For an Idaho food processor running new-formulation trials or a Utah medical-device manufacturer iterating on tooling, the effect was a tax bill on income that had already been spent.

That regime has now been reversed for domestic work. The One Big Beautiful Bill Act (OBBBA), signed in July 2025, added new Section 174A and restored immediate expensing for domestic research and experimental expenditures for tax years beginning after December 31, 2024. The relief is permanent, with no scheduled sunset.

Here is what that means at the plant level, and what to do before year-end filing.

What the OBBBA change actually does

New Section 174A lets manufacturers deduct qualifying domestic research and experimental costs in the year incurred, the same way most operating expenses are treated. There is no more five-year wait for domestic R&D deductions.

Taxpayers who want to smooth income across years can still elect to capitalize domestic costs and amortize them over a period of not less than sixty months, starting in the month the research benefit is first realized. That election is a planning tool, not a punishment.

Foreign R&D was left in the old regime. Costs tied to research performed outside the United States still amortize over fifteen years under Section 174. For most Cooper Norman clients, that split is manageable, but any manufacturer with an offshore engineering group or contract-development spend abroad should segregate those costs cleanly.

Activities that count as Section 174 work

Section 174 covers the broader universe of research and experimental expenditures, which is wider than the qualified research the Section 41 credit rewards. Expenses that typically fall under 174 include:

• Wages and benefits for employees performing or directly supporting research
• Supplies consumed in the research process
• Contract research paid to outside firms
• Software development, including internal-use software
• Overhead reasonably allocated to research activity

Software development remains inside Section 174 by statute, which matters for manufacturers running their own MES, quality, or IoT platforms.

The 2022 through 2024 problem, and what to do about it

The retroactive relief window for small businesses closed on July 6, 2026. Businesses with average annual gross receipts of $31 million or less were allowed to amend 2022, 2023, and 2024 returns to apply immediate domestic expensing. If you were eligible and did not amend, that window is now shut.

Larger manufacturers, and any business that did not amend during the window, will still be carrying unamortized Section 174 balances from prior years. Those balances continue to amortize on the original schedule until fully deducted. Cooper Norman advisors can model out the remaining amortization runway and flag any accounting-method-change filings still available.

Planning moves worth running before year-end

Several decisions can move real dollars for a plant this year:

• Segregate domestic and foreign R&D at the source. Chart-of-accounts changes made in Q4 are far cleaner than trying to split time cards in March.
• Coordinate Section 174A with the Section 41 R&D credit. They are different provisions, and the credit is still available for qualified research on top of immediate expensing.
• Look at software development spend deliberately. Custom software, PLC programming, and MES work often qualify under both 174 and 41 when documented as they occur.
• Model cash flow with the change baked in. Many manufacturers built quarterly estimates around amortized 174. Reforecast now so estimated payments do not overshoot.

What still requires attention

Section 174A is not a blank check. Contemporaneous documentation still matters, and the line between operating expense and Section 174 expenditure is not always obvious. Prototype builds, tooling development, and formulation trials read differently to a plant manager than they do to a revenue agent, and the difference shows up on audit.

For Idaho and Utah manufacturers with growing R&D spend, particularly in food processing, aerospace components, and medical devices, running a mid-year check with your CPA on how Section 174A is being applied is time well spent.

This overview is general information, not tax advice for your specific business. Talk with a Cooper Norman advisor about how these rules apply to your operation, and how they interact with the tax planning you already have in place.